You really can't compare ALS to Ebola.
Ebola is communicable and serves a death sentence in 3 weeks or less.
The FDA only makes exceptions to "outbreaks", i.e. SARS, Swine Flu, Ebola, etc.
Also, the companies that provide the un-approved drugs are not compensated for it.
Those big buy blocks this morning are bullish too, since they came the day before CC. Usually big money has advanced notice of what's going on.
EDAP looked good until the FDA Briefing Docs were released. After I read them, I realized just how incompetent their management really is. Don't feel bad though, I got burned in ACRX, by their management incompetence. During the bio boom I think everyone overlooked management competency, but not anymore. I like ACAD, but bio is just so out of favor right now. Maybe I'll jump in before the CC.
TKM-Ebola is NOT a vaccine. It's being developed as a treatment for Ebola within 72 hours of becoming infected. The experimental serum given to the 2 American workers was NOT TKM-Ebola.
The FDA will NOT lift the hold on TKM-Ebola, but if TKMR wants to submit an NDA to the FDA to treat patients in Africa, they will allow it. However, TKMR is ultra conservative and most likely will NOT enter into Africa.
TKMR stock is being driven by retail momentum and is now in over-bought territory. Be careful at these levels and set tight stops when taking a long position. I'm not long or short the stock, but at these levels is unattractive to make an entry.
1) Strong, fundamental science that has shown to produce a clinical effect with an excellent safety profile in all trials to date.
2) As of the last 10-Q: 86.4M cash on hand with a burn rate of 6M per quarter. Cash will last well into 2016 and be able to fund almost all trials in the pipeline.
3) HIV data from AGS-004 due by the end of the month as per CEO Abbey at the Jeffries Conference on 6/25. This data should be indicative of the mRCC P3 trial which produced great results in P2.
4) NIH awarded a contract for 39.3M in 2006 to fund the HIV trials. For the NIH to grant that much money, they obviously strongly believe in the science.
5) Numerous other trials to start in the 2H 2014.
6) Very small market cap of only 154M as of the close today, making this extremely undervalued with a lot of room to run upon exposure of a positive catalyst this month.
7) IPO price was $8 on 2/7/14. Today's close of 7.25 is trading at almost a 10% discount to the IPO.
8) The 6 month lock up of the IPO won't expire until 8/7/14.
1) Thinly traded so there are wild swings and technicals don't have a major effect. I watched the market maker (MM) manipulate this down all day on trades of 100 shares.
2) As with any bio, clinical trials could fail resulting in large losses.
3) If the P2 trial in HIV produces positive results, a substantial rise in price may mean sell side pressure after 8/7 when the lock up expires.
Based on previous clinical trials, I believe their is a high probability of a positive announcement in the HIV trial by the end of the month. This should result is a major price inflection in the stock price, especially with a small float and 295k shares sold short. I would expect a strong, positive HIV outcome to raise the price to between 12 and 16, which would equate to a market cap of 264M to 356M based on the fully diluted float of 22M shares. Even this is still undervalued IMO, but in today's market I feel this is where the price will rise to.
Looks like the gap is filling and consolidating. Lets see if we hold 21.02. There's some near term support there. The selling trades are pretty light with 2k being the largest suggestive of retail traders. This is just a healthy pullback to set a new trading level prior to the next leg up.
Safe bet to lose your $$$$$. Pffttt, what a clown! VICL will be de-listing within 90 days, then will trade on pinkies. Go pump your POS elsewhere pal.
If it was on the ask, that means someone wanted to dump 220k shares. I'd call that pretty bearish. If it was on the bid, it would've been bullish. Plus, it's only an investor conference. Basically meaningless.
I learned about them years ago. Learned to stay away from that garbage. Obviously you VICL pumpers haven't learned yet. All you have to do is look at the chart. It's pretty simple...down is bad, up is good. VICL = very bad company trying to market fish oil that anyone can buy over the counter. Yeah, big pharma is really pounding on VICL doors. Give me a break. Go pump your VICL trash on your own board and take a hike.